BioCentury | Jul 16, 2012
Company News

Alere sales and marketing update

...D-dimer. Alere (formerly Inverness Medical Inc.) gained the Triage products through its 2007 acquisition of Biosite Inc....
BioCentury | May 24, 2010
Finance

What knight?

...Medical Systems Inc./ Roche (SIX:ROG; OTCQX:RHHBY) 6/25/07 $51.74 $75.00 1/22/08 $85.33 $89.50 73% 19% 5% Biosite Inc./...
BioCentury | May 11, 2009
Company News

Inverness sales and marketing update

...Biosite Inc. subsidiary voluntarily recalled one lot of its Triage Cardiac Panel to diagnose myocardial infarction. Biosite...
BioCentury | Apr 14, 2008
Company News

Adnavance board of directors update

...B.C. Business: Supply/Service, Diagnostic Appointed: Kenneth Buechler, former president of Inverness Medical Innovations Inc. 's Biosite Inc....
BioCentury | Apr 7, 2008
Company News

Compugen, Inverness deal

...Inverness' Biosite Inc. subsidiary will develop and select antibodies that bind to Compugen's CGEN-144 , a variant...
...variant of troponin 1. Troponin 1 is a biomarker used to diagnose myocardial infarction (MI). Biosite...
BioCentury | Dec 24, 2007
Strategy

Platform collecting

...connection with the September MEDX deal, Oxford Genome also expanded on a 2006 deal with Biosite Inc....
...develop companion diagnostics for Oxford Genome's antibody therapeutics using jointly selected cancer targets from OGAP. Biosite...
BioCentury | Nov 12, 2007
Company News

Quidel board of directors update

...Corp. (QDEL), San Diego, Calif. Business: Diagnostic Appointed: Kenneth Buechler, formerly president and CSO of Biosite Inc. WIR...
BioCentury | Sep 24, 2007
Company News

Inverness, Medarex, Oxford Genome Sciences Ltd. deal

...Biosite will receive rights to Oxford Genome's colorectal and ovarian cancer targets for diagnostic uses. Biosite...
BioCentury | Jul 2, 2007
Company News

Biosite, Inverness deal

...it did not already own for $92.50 per share in cash (see BioCentury, May 21). Biosite Inc....
BioCentury | Jun 18, 2007
Strategy

Anatomy of a bidding war

...Anatomy of a bidding war From a position of wanting to go it alone, Biosite's board...
...reported in the SEC filings, in which the identities of several players are masked. Source: Biosite's...
Items per page:
1 - 10 of 286
BioCentury | Jul 16, 2012
Company News

Alere sales and marketing update

...D-dimer. Alere (formerly Inverness Medical Inc.) gained the Triage products through its 2007 acquisition of Biosite Inc....
BioCentury | May 24, 2010
Finance

What knight?

...Medical Systems Inc./ Roche (SIX:ROG; OTCQX:RHHBY) 6/25/07 $51.74 $75.00 1/22/08 $85.33 $89.50 73% 19% 5% Biosite Inc./...
BioCentury | May 11, 2009
Company News

Inverness sales and marketing update

...Biosite Inc. subsidiary voluntarily recalled one lot of its Triage Cardiac Panel to diagnose myocardial infarction. Biosite...
BioCentury | Apr 14, 2008
Company News

Adnavance board of directors update

...B.C. Business: Supply/Service, Diagnostic Appointed: Kenneth Buechler, former president of Inverness Medical Innovations Inc. 's Biosite Inc....
BioCentury | Apr 7, 2008
Company News

Compugen, Inverness deal

...Inverness' Biosite Inc. subsidiary will develop and select antibodies that bind to Compugen's CGEN-144 , a variant...
...variant of troponin 1. Troponin 1 is a biomarker used to diagnose myocardial infarction (MI). Biosite...
BioCentury | Dec 24, 2007
Strategy

Platform collecting

...connection with the September MEDX deal, Oxford Genome also expanded on a 2006 deal with Biosite Inc....
...develop companion diagnostics for Oxford Genome's antibody therapeutics using jointly selected cancer targets from OGAP. Biosite...
BioCentury | Nov 12, 2007
Company News

Quidel board of directors update

...Corp. (QDEL), San Diego, Calif. Business: Diagnostic Appointed: Kenneth Buechler, formerly president and CSO of Biosite Inc. WIR...
BioCentury | Sep 24, 2007
Company News

Inverness, Medarex, Oxford Genome Sciences Ltd. deal

...Biosite will receive rights to Oxford Genome's colorectal and ovarian cancer targets for diagnostic uses. Biosite...
BioCentury | Jul 2, 2007
Company News

Biosite, Inverness deal

...it did not already own for $92.50 per share in cash (see BioCentury, May 21). Biosite Inc....
BioCentury | Jun 18, 2007
Strategy

Anatomy of a bidding war

...Anatomy of a bidding war From a position of wanting to go it alone, Biosite's board...
...reported in the SEC filings, in which the identities of several players are masked. Source: Biosite's...
Items per page:
1 - 10 of 286